Wedbush initiated coverage of Sana Biotechnology (SANA) with an Outperform rating and $5 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- Sana Biotechnology Announces Leadership Transition
- Sana Biotechnology Board Member Resigns Effective August 29
- Sana Biotechnology Reports Q2 2025 Financial Results
- Sana Biotechnology’s Strategic Advances and Positive FDA Feedback Bolster Buy Rating
- Sana Biotechnology’s Promising Advances in Diabetes Treatment and Strong Financial Position Support Buy Rating